Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13494190 | 0.81 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1SYK | |
| SCHEMBL5443101 | 0.80 | CCR6 (0.45) | CTSKCTSLCTSBCTSSKCNA5 | |
| SCHEMBL7439259 | 0.79 | L3MBTL1 (0.43) | L3MBTL1CTSKCTSBSYK | |
| SCHEMBL7775544 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1SYK | |
| SCHEMBL8184106 | 0.76 | CTSK (0.53) | CTSKCTSLCTSBCTSSAAK1 | |
| SCHEMBL21998139 | 0.76 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1SYK | |
| SCHEMBL27853178 | 0.76 | CTSK (0.48) | L3MBTL1CTSKCTSLCTSBCTSS | |
| SCHEMBL13519510 | 0.76 | CTSK (0.48) | L3MBTL1CTSKCTSLCTSBCTSS | |
| SCHEMBL16205770 | 0.76 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1SYK | |
| SCHEMBL19586697 | 0.75 | TPSAB1 (0.46) | L3MBTL1CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | L3MBTL1 3835/4885CTSK 3434/4885CTSL 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.